Abstract
Traditional drug formulations are facing issues of toxicity to normal cells, stability, and bioavailability, calling for suitable nanocarriers such as polymeric nanoparticles for targeting prostate cancer. This chapter reviews the basics of polymeric nanoparticles and targeted treatment of prostate cancer. We detail targeting strategies and types of polymeric nanoparticles.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agarwal S, Dominic A, Wasnik S (2019) An overview of polymeric nanoparticles as potential cancer therapeutics. In: Polymeric nanoparticles as a promising tool for anti-cancer therapeutics. Academic/Elsevier, pp 21–34. https://doi.org/10.1016/B978-0-12-816963-6.00002-9
Alsehli M (2020) Polymeric nanocarriers as stimuli-responsive systems for targeted tumor (cancer) therapy: recent advances in drug delivery. Saudi Pharm J 28:255–265. https://doi.org/10.1016/j.jsps.2020.01.004
Arya A, Ahmad H, Khandelwal K, Agrawal S, Dwivedi AK (2019) Novel multifunctional nanocarrier-mediated codelivery for targeting and treatment of prostate cancer. Nanomater Drug Deliv Therapy:185–224. https://doi.org/10.1016/B978-0-12-816505-8.00008-4. Elsevier
Ast G (2003) Drug-targeting strategies for prostate cancer. Curr Pharm Des 9:455–466. https://doi.org/10.2174/1381612033391603
Barve A, Jin W, Cheng K (2014) Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release 187:118–132. https://doi.org/10.1016/j.jconrel.2014.05.035
Barve A, Jain A, Liu H, Zhao Z, Cheng K (2020) Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy. Acta Biomater 113:501–511. https://doi.org/10.1016/j.actbio.2020.06.019
Behera A, Padhi S (2020) Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review. Environ Chem Lett 18:1557–1567. https://doi.org/10.1007/s10311-020-01022-9
Bharali DJ, Sudha T, Cui H, Mian BM, Mousa SA (2017) Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomed Nanotechnol Biol Med 13:263–273. https://doi.org/10.1016/j.nano.2016.08.017
Bulmahn JC, Kutscher HL, Cwiklinski K, Schwartz SA, Prasad PN, Aalinkeel R (2020) A multimodal theranostic nanoformulation that dramatically enhances docetaxel efficacy against castration resistant prostate cancer. J Pharm Sci 109:2874–2883. https://doi.org/10.1016/j.xphs.2020.06.004
Changizi O, Khoei S, Mahdavian A, Shirvalilou S, Mahdavi SR, Rad JK (2020) Enhanced radiosensitivity of LNCaP prostate cancer cell line by gold-photoactive nanoparticles modified with folic acid. Photodiagnosis Photodyn 29:101602. https://doi.org/10.1016/j.pdpdt.2019.101602
Chen W, Guo M, Wang S (2016) Anti prostate cancer using PEGylated bombesin containing, cabazitaxel loading nano-sized drug delivery system. Drug Dev Ind Pharm 42:1968–1976. https://doi.org/10.1080/03639045.2016.1185438
Chen Y, Deng Y, Zhu C, Xiang C (2020) Anti prostate cancer therapy: aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles. Biomed Pharmacother 127:110181. https://doi.org/10.1016/j.biopha.2020.110181
Chhabra G, Singh CK, Ndiaye MA, Fedorowicz S, Molot A, Ahmad N (2018) Prostate cancer chemoprevention by natural agents: clinical evidence and potential implications. Cancer Lett 422:9–18. https://doi.org/10.1016/j.canlet.2018.02.025
Chiam K, Ricciardelli C, Bianco-Miotto T (2014) Epigenetic biomarkers in prostate cancer: current and future uses. Cancer Lett 342:248–256. https://doi.org/10.1016/j.canlet.2012.02.011
DeFeo-Jones D, Garsky VM, Wong BK, Feng D-M, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P (2000) A peptide–doxorubicin ‘prodrug’ activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 6:1248–1252. https://doi.org/10.1038/81351
Dhas NL, Ige PP, Kudarha RR (2015) Design, optimization and in-vitro study of folic acid conjugated-chitosan functionalized PLGA nanoparticle for delivery of bicalutamide in prostate cancer. Powder Technol 283:234–245. https://doi.org/10.1016/j.powtec.2015.04.053
Espinosa-Cano E, Palao-Suay R, Aguilar MR, Vázquez B, San Román J (2018) Polymeric nanoparticles for cancer therapy and bioimaging. Nanooncology:137–172. https://doi.org/10.1007/978-3-319-89878-0_4. Springer
Evans JC, Malhotra M, Sweeney K, Darcy R, Nelson CC, Hollier BG, O’Driscoll CM (2017) Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours. Int J Pharm 532:511–518. https://doi.org/10.1016/j.ijpharm.2017.09.013
Fagerland S-MT, Berg S, Hill DK, Snipstad S, Sulheim E, Hyldbakk A, Kim J, de Lange DC (2020) Ultrasound-mediated delivery of chemotherapy into the transgenic adenocarcinoma of the mouse prostate model. Ultrasound Med Biol 46:3032–3045. https://doi.org/10.1016/j.ultrasmedbio.2020.07.004
Famuyiwa TO, Kumi-Diaka JK (2018) Nanoparticle (NP) delivery of chemotherapy drugs to prostate cancer patients. J Cancer Prev Curr Res 9:218–220. https://doi.org/10.15406/jcpcr.2018.09.00354
Fang Y, Lin S, Yang F, Situ J, Lin S, Luo Y (2020) Aptamer-conjugated multifunctional polymeric nanoparticles as cancer-targeted, MRI-ultrasensitive drug delivery systems for treatment of castration-resistant prostate cancer. BioMed Res Int 2020. https://doi.org/10.1155/2020/9186583
Feng X, Zhou Y, Xie X, Li M, Huang H, Wang L, Xu X, Yu J (2019) Development of PSMA-targeted and core-crosslinked glycol chitosan micelles for docetaxel delivery in prostate cancer therapy. Mater Sci Eng C 96:436–445. https://doi.org/10.1016/j.msec.2018.11.044
Fitzgerald KA, Malhotra M, Gooding M, Sallas F, Evans JC, Darcy R, O’Driscoll CM (2016) A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor. Int J Pharm 499:131–145. https://doi.org/10.1016/j.ijpharm.2015.12.055
Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C (2015) The global burden of cancer 2013. JAMA Oncol 1:505–527. https://doi.org/10.1001/jamaoncol.2015.0735
Gad A, Kydd J, Piel B, Rai P (2016) Targeting cancer using polymeric nanoparticle mediated combination chemotherapy. Int J Nanomed Nanosurg 2. https://doi.org/10.16966/2470-3206.116
Guo J, O’Driscoll CM, Holmes JD, Rahme K (2016) Bioconjugated gold nanoparticles enhance cellular uptake: a proof of concept study for siRNA delivery in prostate cancer cells. Int J Pharm 509:16–27. https://doi.org/10.1016/j.ijpharm.2016.05.027
Hema S, Thambiraj S, Shankaran DR (2018) Nanoformulations for targeted drug delivery to prostate cancer: an overview. J Nanosci Nanotechnol 18:5171–5191. https://doi.org/10.1166/jnn.2018.15420
Hoang B, Ernsting MJ, Murakami M, Undzys E, Li S-D (2014) Docetaxel–carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer. Int J Pharm 471:224–233. https://doi.org/10.1016/j.ijpharm.2014.05.021
Hoang B, Ernsting MJ, Tang W-HS, Bteich J, Undzys E, Kiyota T, Li S-D (2017) Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. Cancer Lett 410:169–179. https://doi.org/10.1016/j.canlet.2017.09.029
Huerta C, del Rosario AM, Molpeceres J (2015) Nimesulide-loaded nanoparticles for the potential coadjuvant treatment of prostate cancer. Int J Pharm 493:152–160. https://doi.org/10.1016/j.ijpharm.2015.07.027
Isaacson KJ, Jensen MM, Subrahmanyam NB, Ghandehari H (2017) Matrix-metalloproteinases as targets for controlled delivery in cancer: an analysis of upregulation and expression. J Control Release 259:62–75. https://doi.org/10.1016/j.jconrel.2017.01.034
Jiashi L, Yan Z, Jie C, Chaohua W, Meidong L (2009) Research on functional nanoparticles as drug carrier. Acta Chim Sinica 67:2205–2209. https://doi.org/10.1186/s12951-018-0392-8
Jin J, Sui B, Gou J, Liu J, Tang X, Xu H, Zhang Y, Jin X (2014) PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells. PLoS One 9:e112200. https://doi.org/10.1371/journal.pone.0112200
Johansson E, Bill-Axelson A, Holmberg L, Onelöv E, Johansson J-E, Steineck G, 4 SPCGSN (2009) Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol 55:422–432. https://doi.org/10.1016/j.eururo.2008.08.054
Khalid M, El-Sawy HS (2017) Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm 528:675–691
Khuroo T, Verma D, Talegaonkar S, Padhi S, Panda A, Iqbal Z (2014) Topotecan–tamoxifen duple PLGA polymeric nanoparticles: Investigation of in vitro, in vivo and cellular uptake potential. Int J Pharmaceutics 473:384–394. https://doi.org/10.1016/j.ijpharm.2014.07.022
Krishnan S, Diagaradjane P, Cho SH (2010) Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy. Int J Hyperthermia 26:775–789. https://doi.org/10.3109/02656736.2010.485593
Kumari P, Ghosh B, Biswas S (2016) Nanocarriers for cancer-targeted drug delivery. J Drug Target 24:179–191. https://doi.org/10.3109/1061186X.2015.1051049
Lin F, Wen D, Wang X, Mahato RI (2019) Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer. Biomaterials 192:95–108. https://doi.org/10.1016/j.biomaterials.2018.10.036
Liu T, Huang Q (2016) Biodegradable brush-type copolymer modified with targeting peptide as a nanoscopic platform for targeting drug delivery to treat castration-resistant prostate cancer. Int J Pharm 511:1002–1011. https://doi.org/10.1016/j.ijpharm.2016.08.017
Liu Y, Guo Q, Sun H, Guo N, Zhang J (2020) Improved therapeutic efficiency of photothermal treatment and nursing care in prostate cancer by DOX loaded PEG coated Cu@ Se nano-hybrid vesicle. Process Biochem. https://doi.org/10.1016/j.procbio.2020.02.022
Menon JU, Tumati V, Hsieh JT, Nguyen KT, Saha D (2015) Polymeric nanoparticles for targeted radiosensitization of prostate cancer cells. J Biomed Mater Res A 103:1632–1639. https://doi.org/10.1002/jbm.a.35300
Mohamed NE, Bovbjerg DH, Montgomery GH, Hall SJ, Diefenbach MA (2012) Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer. Urol Oncol Semin Original Investig:804–812. https://doi.org/10.1016/j.urolonc.2011.02.002. Elsevier
Mohammed MN, Yusoh KB, Shariffuddin JHBH (2018) Poly (N-vinyl caprolactam) thermoresponsive polymer in novel drug delivery systems: a review. Mater Express 8:21–34. https://doi.org/10.1166/mex.2018.1406
Morshed N, Jahan N, Penheiro DE (2018) Polymeric nanoparticles for targeted delivery in cancer treatment: an overview. Int J Pharm Sci Rev Res 19:101–111
Mura S, Nicolas J, Couvreur P (2013) Stimuli-responsive nanocarriers for drug delivery. Nat Mater 12:991–1003. https://doi.org/10.1038/nmat3776
Nagesh PK, Johnson NR, Boya VK, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW (2016) PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces 144:8–20. https://doi.org/10.1016/j.colsurfb.2016.03.071
Nassir AM, Shahzad N, Ibrahim IA, Ahmad I, Md S, Ain MR (2018) Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells. Saudi Pharm J 26:876–885. https://doi.org/10.1016/j.jsps.2018.03.009
Navya P, Kaphle A, Srinivas S, Bhargava SK, Rotello VM, Daima HK (2019) Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg 6:23. https://doi.org/10.1186/s40580-019-0193-2
Nilsson S, Norlén BJ, Widmark A (2004) A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 43:316–381. https://doi.org/10.1080/02841860410030661
Oh S, Crommie MF, Cohen ML (2019) Simulating the nanomechanical response of cyclooctatetraene molecules on a graphene device. ACS Nano 13:1713–1718. https://doi.org/10.1021/acsnano.8b07781
Orive G, Hernández RM, Gascón AR, Pedraz JL (2005) Micro and nano drug delivery systems in cancer therapy. Cancer Ther 3:131–138
Padhi S, Behera A (2020) Nanotechnology based targeting strategies for the delivery of Camptothecin. In: Ankit S, Panda Amulya K, Eric L (eds) Pharmaceutical technology for natural products delivery, impact of nanotechnology. Springer, Cham, pp 243–272
Padhi S, Mirza M, Verma D, Khuroo T, Panda A, Talegaonkar S et al (2015) Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro behavior and tumor amelioration potential. Drug Del 23:2827–2837. https://doi.org/10.3109/10717544.2015.1105323
Padhi S, Kapoor R, Verma D, Panda A, Iqbal Z (2018) Formulation and optimization of topotecan nanoparticles: In vitro characterization, cytotoxicity, cellular uptake and pharmacokinetic outcomes. J Photochem Photobiol B Biol 183:222–232. https://doi.org/10.1016/j.jphotobiol.2018.04.022
Padhi S, Nayak A, Behera A (2020) Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother 131:110708. https://doi.org/10.1016/j.biopha.2020.110708
Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, Mercer R, Van Bokhoven A, Torkko KC, Agarwal C (2019) Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. Cancer Med 8:1110–1123. https://doi.org/10.1002/cam4.1885
Parenky AC, Akalkotkar A, Mulla NS, D'Souza MJ (2019) Harnessing T-cell activity against prostate cancer: a therapeutic microparticulate oral cancer vaccine. Vaccine 37:6085–6092. https://doi.org/10.1016/j.vaccine.2019.08.033
Parveen S, Sahoo SK (2008) Polymeric nanoparticles for cancer therapy. J Drug Target 16:108–123. https://doi.org/10.1080/10611860701794353
Pearce AK, Simpson JD, Fletcher NL, Houston ZH, Fuchs AV, Russell PJ, Whittaker AK, Thurecht KJ (2017) Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic. Biomaterials 141:330–339. https://doi.org/10.1016/j.biomaterials.2017.07.004
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760. https://doi.org/10.1038/nnano.2007.387
Poudel K, Thapa RK, Gautam M, Ou W, Soe ZC, Gupta B, Ruttala HB, Thuy HN, Dai PC, Jeong J-H (2019) Multifaceted NIR-responsive polymer-peptide-enveloped drug-loaded copper sulfide nanoplatform for chemo-phototherapy against highly tumorigenic prostate cancer. Nanomed Nanotechn Biol Med 21:102042. https://doi.org/10.1016/j.nano.2019.102042
Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63. https://doi.org/10.14740/wjon1191
Reddy NS, Rao K (2016) Polymeric hydrogels: recent advances in toxic metal ion removal and anticancer drug delivery applications. Indian J Adv Chem Sci 4:214–234
Rivero-Buceta EM, Donoso C-DV, Manzano VM, Asunción PB (2019) Focal treatment in prostate cancer with anti-PSMA labelled mesoporous silica nanoparticles. Chem Silica Zeolite-Based Mater:413–429. https://doi.org/10.1016/B978-0-12-817813-3.00022-5. Elsevier
Salaam A, Dean D, Thomas V (2018) Nanodiamonds as “magic bullets” for prostate cancer theranostics. Drug Deliv Nanosyst Biomed Appl:333–356. https://doi.org/10.1016/B978-0-323-50922-0.00015-8. Elsevier
Schirrmacher V (2019) From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol 54:407–419. https://doi.org/10.3892/ijo.2018.4661
Shitole AA, Sharma N, Giram P, Khandwekar A, Baruah M, Garnaik B, Koratkar S (2020) LHRH-conjugated, PEGylated, poly-lactide-co-glycolide nanocapsules for targeted delivery of combinational, chemotherapeutic drugs Docetaxel and Quercetin. Mater Sci Eng C:111035. https://doi.org/10.1016/j.msec.2020.111035
Siege R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. Ca Cancer J Clin 64:9–29. https://doi.org/10.3322/caac.21208
Singh SK, Lillard JW Jr, Singh R (2018) Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Lett 427:49–62. https://doi.org/10.1016/j.canlet.2018.04.017
Thangavel S, Yoshitomi T, Sakharkar MK, Nagasaki Y (2015) Redox nanoparticles inhibit curcumin oxidative degradation and enhance its therapeutic effect on prostate cancer. J Control Release 209:110–119. https://doi.org/10.1016/j.jconrel.2015.04.025
Thapa RK, Nguyen HT, Jeong J-H, Shin BS, Ku SK, Choi H-G, Yong CS, Kim JO (2017) Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers. Nanomed Nanotechnol Biol Med 13:885–896. https://doi.org/10.1016/j.nano.2016.12.010
Tousi MS, Sepehri H, Khoee S, Farimani M, Delphi L, Mansourizadeh F (2020) Evaluation of apoptotic effects of mPEG-b-PLGA coated iron oxide nanoparticles as a eupatorin carrier on DU-145 and LNcaP human prostate cancer cell lines. J Pharm Anal. https://doi.org/10.1016/j.jpha.2020.04.002
Vauthier C, Bouchemal K (2009) Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 26:1025–1058. https://doi.org/10.1007/s11095-008-9800-3
Verma D, Thakur P, Padhi S, Khuroo T, Talegaonkar S, Iqbal Z (2017) Design expert assisted nanoformulation design for co-delivery of topotecan and thymoquinone: optimization, in vitro characterization and stability assessment. J Mol Liq 242:382–394. https://doi.org/10.1016/j.molliq.2017.07.002
von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BY (2017) Breaking down the barriers to precision cancer nanomedicine. Trends Biotechnol 35:159–171. https://doi.org/10.1016/j.tibtech.2016.07.006
Wadajkar AS, Menon JU, Tsai Y-S, Gore C, Dobin T, Gandee L, Kangasniemi K, Takahashi M, Manandhar B, Ahn J-M (2013) Prostate cancer-specific thermo-responsive polymer-coated iron oxide nanoparticles. Biomaterials 34:3618–3625. https://doi.org/10.1016/j.biomaterials.2013.01.062
Wang Q, Zhang X, Sun Y, Wang L, Ding L, Zhu W-H, Di W, Duan Y-R (2019) Gold-caged copolymer nanoparticles as multimodal synergistic photodynamic/photothermal/chemotherapy platform against lethality androgen-resistant prostate cancer. Biomaterials 212:73–86. https://doi.org/10.1016/j.biomaterials.2019.05.009
Yan J, Wang Y, Jia Y, Liu S, Tian C, Pan W, Liu X, Wang H (2017) Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer. Biomed Pharmacother 88:374–383. https://doi.org/10.1016/j.biopha.2016.12.138
Yang R, Mondal G, Wen D, Mahato RI (2017) Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer. Nanomed Nanotechnol Biol Med 13:391–401. https://doi.org/10.1016/j.nano.2016.07.017
Yeh C-Y, Hsiao J-K, Wang Y-P, Lan C-H, Wu H-C (2016) Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer. Biomaterials 99:1–15. https://doi.org/10.1016/j.biomaterials.2016.05.015
Yuan X, Liu L, Wang W, Gao Y-r, Zhang D, Jia T-t, Zeng H-r, Pan G, Yuan Y (2020) Development of (G3-C12)-mediated camptothecin polymeric prodrug targeting to Galectin-3 receptor against androgen-independent prostate cancer. Int J Pharms 580:119123. https://doi.org/10.1016/j.ijpharm.2020.119123
Zhang T, Xue X, He D, Hsieh J-T (2015) A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA. Cancer Lett 365:156–165. https://doi.org/10.1016/j.canlet.2015.05.003
Zhang X, Han L, Liu M, Wang K, Tao L, Wan Q, Wei Y (2017a) Recent progress and advances in redox-responsive polymers as controlled delivery nanoplatforms. Mater Chem Front 1:807–822. https://doi.org/10.1016/j.msec.2020.111536
Zhang X, Liu N, Shao Z, Qiu H, Yao H, Ji J, Wang J, Lu W, Chen RC, Zhang L (2017b) Folate-targeted nanoparticle delivery of androgen receptor shRNA enhances the sensitivity of hormone-independent prostate cancer to radiotherapy. Nanomed Nanotechnol Biol Med 13:1309–1321. https://doi.org/10.1016/j.nano.2017.01.015
Zhang J, Zhou J, Yuan Q, Zhan C, Shang Z, Gu Q, Zhang J, Fu G, Hu W (2020) Characterization of ginsenoside compound K loaded ionically cross-linked carboxymethyl chitosan–calcium nanoparticles and its cytotoxic potential against prostate cancer cells. J Ginseng Res. https://doi.org/10.1016/j.jgr.2020.01.007
Acknowledgment
The authors are thankful to the Indian Council of Medical Research (ICMR) for Research Funding (No.5/4–5/159/Neuro/2015-NCDI), and H. R. Patel Institute of Pharmaceutical Education and Research, for providing necessary facilities.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nangare, S.N. et al. (2022). Polymeric Nanoplatforms for the Targeted Treatment of Prostate Cancer. In: Padhi, S., Behera, A., Lichtfouse, E. (eds) Polymeric nanoparticles for the treatment of solid tumors. Environmental Chemistry for a Sustainable World, vol 71. Springer, Cham. https://doi.org/10.1007/978-3-031-14848-4_16
Download citation
DOI: https://doi.org/10.1007/978-3-031-14848-4_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14847-7
Online ISBN: 978-3-031-14848-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)